Dust Mite Allergy Vaccine Research: Where It Stands and What Works Now

A “vaccine” that switches off dust mite allergy has been a research goal for years. Early lab studies, such as particle-based vaccines tested in mice at the University of Iowa, have shown promise, but none has reached patients. Meanwhile, there already is a proven way to train the immune system to tolerate dust mites: allergy immunotherapy, given as shots or as an FDA-approved under-the-tongue tablet.

This guide explains what the experimental research showed, why lab results don’t always translate to people, and the treatments available today. For more, see our dust mite guides.

Jump to: Quick answer · The Iowa mouse study · From lab to patients · Treatments available now · Reducing exposure at home · FAQ

Quick answer

• No dust mite vaccine is available outside of research.
• A 2014 mouse study found that tiny biodegradable particles carrying an immune-boosting signal (CpG), given with a dust mite allergen, prevented airway overreaction to that allergen.
• Promising lab results can fail in people: a cat allergy immunotherapy that did well in earlier trials failed its large phase III trial in 2016 because placebo worked almost as well.
• Proven options exist today: allergy shots, and Odactra, an FDA-approved dust mite tablet for ages 5 to 65.
• Reducing exposure at home still matters alongside any treatment.

The University of Iowa mouse study

In a 2014 study in The AAPS Journal, University of Iowa researchers packaged CpG, a DNA sequence that stimulates the immune system, inside tiny particles made of PLGA, a biodegradable polymer. They vaccinated mice with the particles plus Der p 2, a major dust mite allergen, then exposed the mice to Der p 2 in the nose daily for 10 days.

• All particle sizes containing CpG prevented airway hyperresponsiveness, an asthma-like overreaction of the airways.
• Smaller particles reduced airway inflammation more, including fewer eosinophils, a type of allergy-related white blood cell.
• CpG shifted the immune response toward a type (Th1) that’s less associated with allergy.
• Size mattered: large empty particles without CpG actually increased IgE, the allergy antibody, and airway overreaction.

The authors concluded that particle size and CpG both play a major role in preventing dust mite allergy in this model. But this was in mice, with a single allergen, over a short period.

Why lab results don’t guarantee a treatment

Allergy research has many examples of promising early results that didn’t hold up in large human trials. A cautionary example is a cat allergy treatment once mentioned alongside dust mite vaccines. Cat-PAD, a mix of seven short peptides from the main cat allergen, showed symptom reductions after a short course of injections in earlier studies. But in 2016, its developer Circassia announced that the large phase III trial, with more than 1,200 participants, did not meet its primary goal because placebo produced a similarly large improvement.

For any new allergy vaccine, the path runs through human safety studies, then larger trials against placebo, then regulatory review, which takes years.

Treatments available now

Immunotherapy is the closest thing to a dust mite “vaccine” available today. Read allergy drops vs allergy shots for a full comparison, and how common dust mite allergy is and how it’s diagnosed.

Reducing dust mite exposure at home

• Use allergen-proof covers on the mattress, box spring and pillows as part of a broader plan; see mattress and pillow covers.
• Wash bedding weekly in water of at least 130°F (54.4°C); see does a dryer kill dust mites?
• Keep indoor humidity below 50%; see humidity control for allergies.
• Cut clutter and, where possible, replace bedroom carpet.

This guide is general information, not medical advice. Read our medical disclaimer.

Frequently asked questions

Is there a vaccine for dust mite allergy?

Not yet. Experimental vaccines have been tested in animals, but none is approved. Allergy shots and the Odactra tablet are the available options that build tolerance.

What did the University of Iowa dust mite vaccine study find?

In mice, tiny biodegradable particles carrying CpG prevented airway overreaction to a dust mite allergen and shifted the immune response away from allergy. It hasn’t been tested in people.

Is Odactra a vaccine?

Not in the usual sense. It’s an allergy immunotherapy tablet containing dust mite allergen, approved by the FDA for ages 5 to 65.

How long do dust mite allergy shots take to work?

Treatment usually runs 3 to 5 years. Mayo Clinic says symptoms usually improve during the first year, with the most noticeable improvement often in the second.

What happened to the cat allergy vaccine?

Circassia’s cat allergy immunotherapy failed its phase III trial in 2016 because placebo worked about as well.

Sources

• Joshi VB, Adamcakova-Dodd A, Jing X, et al. Development of a poly(lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy. AAPS J. 2014;16(5):975-985.
• Worm M, Patel D, Creticos PS. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis. Expert Opin Investig Drugs. 2013;22(10):1347-1357.
• Circassia. Circassia announces top-line results from cat allergy phase III study. June 20, 2016.
• American Academy of Allergy, Asthma and Immunology. Sublingual immunotherapy (SLIT) allergy tablets. March 2026.
• Mayo Clinic Staff. Allergy shots. April 13, 2024.

Last reviewed: October 21, 2026.